One of Maryland’s best-funded biotech companies took a milestone first step Monday, announcing it has begun clinical trials of a medication it is developing. Gaithersburg-based Viela Bio was spun out of MedImmune, a subsidiary of AstraZeneca, last month with $250 million in financing and a promise of creating 100 jobs within five years.